Condition: Central Nervous System Neoplasm · Cranial Nerve Disorder · Metastatic Malignant Neoplasm in the Brain · Sponsor: OHSU Knight Cancer Institute
This phase II trial studies how well gadolinium and ferumoxytol magnetic resonance imaging (MRI) work in diagnosing patients with abnormalities in the central nervous system. Diagnostic procedures, such as gadolinium and ferumoxytol MRI, may help find and diagnose abnormalities in the central nervous system.
This description comes directly from the study's public registry record.
Amy E Huddleston, MPA:HA, CCRP · 5034942910 · huddlesa@ohsu.edu
Lisa C Muir, MPA:HA, CCRP · 5034942910 · bennetli@ohsu.edu
Always discuss trial participation with your own doctor first.
| OHSU Knight Cancer Institute | Portland, Oregon, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03270059